Literature DB >> 15019427

Brain-stimulation reward, morphine-induced oral stereotypy, and sensitization: implications for abuse.

Conan Kornetsky1.   

Abstract

Early professionals believed that it was unlikely that anyone but the emotionally unstable received pleasure and became addicted to narcotic drugs. This position was well entrenched and influenced much of the thinking well into the latter half of the last century. Although the discovery of a brain reward system was made early in the 1950's it was not until 20 years later that this discovery was applied to the study of the mechanisms involved in the rewarding aspects of abused substances. Along this vein results will be shown in which opiate antagonist block the dopamine agonist activation of the brain reward system as well as the corollary. Sensitization of the reward system suggests that a driving force for drug use is 'liking' and not just 'wanting.' Basal changes in cerebral metabolic rates of glucose are seen in the presence of cues associated with morphine experience, giving evidence for the role of drug related cues in craving. Finally we asked the question 'Do old rats have as much fun as young rats?'

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15019427     DOI: 10.1016/j.neubiorev.2003.11.014

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  19 in total

1.  Evaluation of reward processes in an animal model of depression.

Authors:  David A Slattery; Athina Markou; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2006-12-20       Impact factor: 4.530

Review 2.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

3.  PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats.

Authors:  Amanda E Higley; Krista Spiller; Peter Grundt; Amy Hauck Newman; Stephen W Kiefer; Zheng-Xiong Xi; Eliot L Gardner
Journal:  J Psychopharmacol       Date:  2010-02-08       Impact factor: 4.153

4.  Cocaine- and morphine-induced synaptic plasticity in the nucleus accumbens.

Authors:  Adriana A Alcantara; Helen Y Lim; Christopher E Floyd; Juanita Garces; John M Mendenhall; Chelsea L Lyons; Monica L Berlanga
Journal:  Synapse       Date:  2010-10-11       Impact factor: 2.562

5.  Development of tolerance and sensitization to different opioid agonists in rats.

Authors:  Gisela Grecksch; Katharina Bartzsch; Antje Widera; Axel Becker; Volker Höllt; Thomas Koch
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

6.  Beta-endorphin levels in longtailed and pigtailed macaques vary by abnormal behavior rating and sex.

Authors:  Carolyn M Crockett; Gene P Sackett; Curt A Sandman; Aleksandra Chicz-DeMet; Kathleen L Bentson
Journal:  Peptides       Date:  2007-07-19       Impact factor: 3.750

7.  The selective dopamine D3 receptor antagonists SB-277011A and NGB 2904 and the putative partial D3 receptor agonist BP-897 attenuate methamphetamine-enhanced brain stimulation reward in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xiao-Qing Peng; Amy H Newman; Charles R Ashby; Christian Heidbreder; József Gaál; Eliot L Gardner
Journal:  Psychopharmacology (Berl)       Date:  2007-11-06       Impact factor: 4.530

8.  Augmentation of morphine-induced sensitization but reduction in morphine tolerance and reward in delta-opioid receptor knockout mice.

Authors:  V I Chefer; T S Shippenberg
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

Review 9.  Neurotrophins in the ventral tegmental area: Role in social stress, mood disorders and drug abuse.

Authors:  E M Nikulina; C E Johnston; J Wang; R P Hammer
Journal:  Neuroscience       Date:  2014-05-27       Impact factor: 3.590

Review 10.  Agmatine and imidazoline receptors: their role in opioid analgesia, tolerance and dependence.

Authors:  Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2007-07-25       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.